Providing independent clinical excellence since 2005
LDL-C alone may miss important cardiovascular risk. This article explains why ApoB and small dense LDL often better reflect atherosclerotic burden, especially in metabolic disease and high visceral fat. It outlines practical lipid targets by risk category and shows how LDL-C:ApoB ratios can estimate dangerous particle patterns
The keto and Atkins diets have profound effects on hepatic lipid metabolism, and hence on LDL cholesterol handling. Let’s unpack this carefully through the lens of the endogenous cholesterol pathway.
Bempedoic acid offers a new avenue for patients who require an alternative to statins for managing high cholesterol. Its liver-specific action and excellent safety and side effect profile make it a valuable addition to available treatments we can use to combat high LDL cholesterol levels to reduce coronary inflammation and stabilise high risk coronary plaque.
This article looks into the role of PCSK9, the development of PCSK9 inhibitors, their efficiency, and their potential as a game-changer in the management of cardiovascular diseases. It provides a short exploration of the subject, drawing upon the most recent and relevant research and guidelines.